1 .- Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation 2003;108:1546–51.

2 .- Ayyobi AF, Brunzell JD. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. Am J Cardiol 2003;92:27–33J.

3 .- Festa A, D’Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation 2000;102:42–7.

4 .- Messerli AW, Seshadri N, Pearce GL, et al. Relation of albumin/creatinine ratio to C-reactive protein and to metabolic syndrome. Am J Cardiol 2003;92:610–12.

5 .-Vaisanen S, Baumstark MW, Penttila I, et al. Small, dense LDL particle concentration correlates with plasminogen activator inhibitor type-1 (PAI-1) activity. Thromb Haemost 1997;78:1495–9.6 .- Corella D, Ordovas JM. The metabolic syndrome: a crossroad for genotypephenotype associations in atherosclerosis. Curr Atheroscler Rep 2004;6:186–96.

7 .- Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595–607.

8. -Semenkovich CF. Fatty acid metabolism and vascular disease. Trends Cardiovasc Med 2004;14:72–6.

9. - Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539–53.

10 .- Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001;285:2486–97.

11 .- Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA 2002;287:356–9.

12. - Lakka HM, Lakka TA, Tuomilehto J, et al. Abdominal obesity is associated with increased risk of acute coronary events in men. Eur Heart J 2002;23:706–13.

13 .- Hsia J, Bittner V, Tripputi M, et al. Metabolic syndrome and coronary angiographic disease progression: the women’s angiographic vitamin and estrogen trial. Am Heart J 2003;146:439–45.

14 .- Balkau B, Charles MA, Drivsholm T, et al. European Group for the study of insulin resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28:364–76.

15 .- Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683–9

16 .- Meigs JB, Wilson PW, Nathan DM, et al. Prevalence and characteristics of the metabolic syndrome in the San Antonio heart and Framingham offspring studies. Diabetes 2003;52:2160–7.

17 .- Ravussin E, Valencia ME, Esparza J, et al. Effects of a traditional lifestyle on obesity in Pima Indians. Diabetes Care 1994;17:1067–74.

18 .- K, Boutin P, Froguel P. Genetics of obesity. Am J Pharmacogenomics 2002;2:177–87.

19 .- Matsuzawa Y, Funahashi T, Kihara S, et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24:29–33

20 .- Malczewska-Malec M, Wybranska I, Leszczynska-Golabek I, et al. Analysis of candidate genes in Polish families with obesity. Clin Chem Lab Med 2004;42:487–93.

21 .- Merkel M, Eckel RH, Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res 2002;43:1997–2006.

22 .- Van Dijk KW, Rensen PC, Voshol PJ, et al. The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism? Curr Opin Lipidol 2004;15:239–46.

23 .- Ashavaid TF, Shalia KK, Kondkar AA, et al. Gene polymorphism and coronary risk factors in Indian population. Clin Chem Lab Med 2002;40:975–85.

24 .- Lee KW, Ayyobi AF, Frohlich JJ, et al. APOA5 gene polymorphism modulates levels of triglyceride, HDL cholesterol and FER(HDL) but is not a risk factor for coronary artery disease. Atherosclerosis 2004;176:165–72

25 .- Morabia A, Ross BM, Costanza MC, et al. Population-based study of SR-BI genetic variation and lipid profile. Atherosclerosis 2004;175:159–68.

26 .- Wang Y, Kurdi-Haidar B, Oram JF. LXR-mediated activation of macrophage stearoyl-CoA desaturase generates unsaturated fatty acids that destabilize ABCA1. J Lipid Res 2004;45:972–80

27 .- Gudnason V, Kakko S, Nicaud V, et al. Cholesteryl ester transfer protein gene effect on CETP activity and plasma high-density lipoprotein in European populations. The EARS Group. Eur J Clin Invest 1999;29:116–28.

28 .- Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a meta-analysis. Arterioscler Thromb Vasc Biol 2003;23:1269–75.

29 .- Ji Q, Ikegami H, Fujisawa T, et al. A common polymorphism of uncoupling protein 2 gene is associated with hypertension. J Hypertens 2004;22:97–102.

30 .- Wang JG, Liu L, Zagato L, et al. Blood pressure in relation to three candidate genes in a Chinese population. J Hypertens 2004;22:937–44.

31 .- Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk 2000;7:325–31.

32. - JG Jr. Dyslipidemia and coronary artery disease. Can J Cardiol 2000;16(suppl A):3–4A.

33 .- Ninomiya JK, L’Italien G, Criqui MH, et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey. Circulation


34 .- Anderson JL, Horne BD, Jones HU, et al, for the intermountain heart collaborative (IHC) study. Which features of the metabolic syndrome predict the prevalence and clinical outcomes of angiographic coronary artery disease? Cardiology 2004;101:185–93.

35. - Sacco RL, Benson RT, Kargman DE, et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan stroke study. JAMA 2001;285:2729–35.

36. - Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001;60:329–39.

37 .- Haluzik M, Parizkova J, Haluzik MM. Adiponectin and its role in the obesityinduced insulin resistance and related complications. Physiol Res 2004;53:123–9.

38 .- Beltowski J. Adiponectin and resistin--new hormones of white adipose tissue. Med Sci Monit 2003;9:RA55–61. 39 Drayna D, Jarnagin AS, McLean J, et al. Cloning and sequencing of the human cholesteryl ester transfer protein cDNA. Nature 1987;327:632–4.

40 .- Morton RE. Cholesteryl ester transfer protein and its plasma regulator: lipid transfer inhibitor protein. Curr Opin Lipidol 1999;10:321–7.

41 .- Arai T, Yamashita S, Hirano K, et al. Increased plasma cholesteryl ester transfer protein in obese subjects: a possible mechanism for the reduction of serum HDL cholesterol levels in obesity. Arterioscler Thromb 1994;14:1129–36.

42 .-Gorter PM, Olijhoek JK, van der Graaf Y, et al, SMART Study Group. Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis 2004;173:363–9.

43 .- Lewis GF, Uffelman KD, Szeto LW, et al. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 1995;95:158–66.

44 .- Princen BHCMT, Romijn JA, Bisschop PH, et al. Endogenous cholesterol synthesis is associated with VLDL-2 apoB-100 production in healthy humans. J Lipid Res 2003;44:1341–8.

45 .- Malmstro¨ m R, Packard CJ, Watson TD, et al. Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 1997;17:1454–64.

46 .- Lewis GF, Uffelman KD, Szeto LW, et al. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes 1993;42:833–42.

47 .- Goldstein BJ. Insulin resistance: from benign to type 2 diabetes mellitus. Rev Cardiovasc Med 2003;4:S3–10.

48 .- McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001;86:713–18.

49 .- Kwiterovich PO Jr. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am J Cardiol 2002;90:30–47i.

50 .- Packard CJ, Demant T, Stewart JP, et al. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res 2000;41:305–18.

51 .- Ginsberg HN, Le N-A, Goldberg IJ, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins C-III and AI: evidence that apolipoprotein C-III inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986;78:1287–95.

52 .- Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 2003;31:1066–9.

53 .-Lamarche B, Tchernof A, Mauriege P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998;279:1955–61.

54 .- Chait A, Brazg RL, Tribble DL, et al. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993;94:350–6.

55 .- Kwiterovich PO Jr, Coresh J, Smith HH, et al. Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease. Am J Cardiol


56 .- Kwiterovich PO Jr, Coresh J, Bachorik PS. Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged , or = 50 years) and women (,or = 60 years) with coronary arterydisease. Am J Cardiol 1993;71:631–9

57 .- Wilson PW, Grundy SM. The metabolic syndrome: practical guide to origins and treatment: part I. Circulation 2003;108:1422–4.

58 .- Rust S, Rosier M, Funke H, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet1999;22:352–5.

59 .- Kolovou G, Cokkinos DV. Low serum levels of high-density lipoprotein cholesterol and hypolipidaemic treatment. Curr Med Res Opin 2002;18:265–8.

60 .- Kolovou G, Daskalova D, Petropoulos I, et al. Effect of baseline levels on response of high density lipoprotein cholesterol to hypolipidemic treatment. Am J Cardiol 2003;92:1339–42.

61 .- Robins SJ. Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs high-density lipoprotein intervention trial. Am J Cardiol 2001;88:19–23N.

62 .- Taira K, Hikita M, Kobayashi J, et al. Delayed post-prandial lipid metabolism in subjects with intra-abdominal visceral fat accumulation. Eur J Clin Invest1999;29:301–8.

63 .- Rebuffe-Scrive M, Lonnroth P, Marin P, et al. Regional adipose tissue metabolism in men and postmenopausal women. Int J Obes 1987;11:347–55.

64 .- Couillard C, Bergeron N, Prud’homme D, et al. Postprandial triglyceride response in visceral obesity in men. Diabetes 1998;47:953–60.

65 .- Mazzone T, Foster D, Chait A. In vivo stimulation of low-density lipoprotein degradation by insulin. Diabetes 1984;33:333–8.

66 .- Cummings MH, Watts GF, Umpleby AM, et al. Acute hiperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetes 1995;44:1059–65.

67 .- AD. Hepatic uptake of chylomicron remnants. J Lipid Res 1997;38:2173–92.

68 .- Thompson GR, Naoumova RP, Watts GF. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res 1996;37:439–47.

69 .- Patsch JR, Miesenbock G, Hopferwieser T, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. ArteriosclerThromb 1992;12:1336–45.

70 .- Kolovou GD, Daskalova D, Iraklianou SA, et al. Postprandial lipemia in hypertension. J Am Coll Nutr 2003;22:80–7.

71 .- Kolovou G, Anagnostopoulou K, Pilatis N, et al. Heterozygote men with familial hypercholesterolaemia (FH) may have an abnormal triglyceride response postprandially. Evidence for another predictor of vascular risk in FH. Int J Clin Practice 2005;59:311–17.

72 .- Steinberger J, Daniels SR, for American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young); American Heart Association Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation 2003;107:1448–53.

73 .- Vinicor F. Is diabetes a public-health disorder? Diabetes Care 1994;17 (suppl 1):22–7

74 .- Pinhas-Hamiel O, Dolan LM, Daniels SR, et al. Increased incidence of noninsulin-dependent diabetes mellitus among adolescents. J Pediatr 1996;128:608–15.

75 .- Boden G. Fatty acids and insulin resistance. Diabetes Care 1996;19:394–5.

76 .- Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–34.

77 .- Ayyobi AF, Brunzell JD. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. Am J Cardiol 2003;92:27–33J.

78 .- Goldstein J, Schrott H, Hazzard W. Hyperlipidemia in coronary heart disease, II: genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973;52:1544–68.

79 .- Rainwater DL, Mitchell BD, Mahaney MC, et al. Genetic relationship between measures of HDL phenotypes and insulin concentrations. Arterioscler Thromb Vasc Biol 1997;17:3414–19.

80 .- Sniderman AD, Castro Cabezas M, Ribalta J, et al. A proposal to redefine familial combined hyperlipidaemia -- third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the scientific sessions of the European Society for Clinical Investigation. Eur J Clin Invest 2002;32:71–3.

81 .- Jarvik GP, Brunzell JD, Austin MA, et al. Genetic predictors of FCHL in four large pedigrees. Influence of ApoB level major locus predicted genotype and LDL subclass phenotype. Arterioscler Thromb 1994;14:1687–94.

82 .- Chan DC, Barrett HP, Watts GF. Dyslipidemia in visceral obesity: mechanisms, implications, and therapy. Am J Cardiovasc Drugs 2004;4:227–46.

83 .-Knopp RH, Walden CE, Retzlaff BM, et al. Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men: the dietary alternatives study. JAMA


84 .- Sudhop T, Lu¨tjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106:1943–8.

85 .-Simonen P, Gylling H, Howard AN, et al. Introducing a new component of the metabolic syndrome: low cholesterol absorption. Am J Clin Nutr 2000;72:82–8.

86 .- Chan DC, Watts GF, Barrett PHR, et al. Relationships between cholesterol homeostasis and triacylglycerol-rich lipoprotein remnant metabolism in the metabolic syndrome. Clin Sci 2003;104:383–8.

87 .- Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air force/Texas coronary atherosclerosis prevention study. JAMA 1998;279:1615–22.

88 .- Keech A, Colquhoun D, Best J, et al, for LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003;26:2713–21.

89 .- Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators.Circulation 1998;98:2513–19.

90 .- Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian simvastatin survival study. Arch Intern Med 1999;159:2661–7.

91 .- Collins R, Armitage J, Parish S, et al, Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005–16.

92 .- Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland coronary prevention study. Circulation2003;108:414–19.

93 .- Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410–18.

94 .- Canner PL, Furberg CD, Terrin ML, et al. Niacin decreases myocardial infarction and total mortality in patients with metabolic syndrome: results from the coronary drug project. J Am Coll Cardiol 2003;41(suppl A):291A.

95 .- Tato` F, Vega GL, Grundy SM. Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase. Am J Cardiol 1998;81:805–8.

96 .- Karpe F, Frayn KN. The nicotinic acid receptor--a new mechanism for an old drug. Lancet 2004;363:1892–4.

97 .- Rubic T, Trottmann M, Lorenz RL. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 2004;67:411–19.98 .- Staels B, Auwerx J. Regulation of apo A-I gene expression by fibrates. Atherosclerosis 1998;137:S19–23.

99 .- Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088–93.

100 .- Gervois P, Torra IP, Fruchart JC, et al. Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin Chem Lab Med 2000;38:3–11.

101 .- Chinetti G, Gbaguidi FG, Griglio S, et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation


102 .- Martin G, Duez H, Blanquart C, et al. Statin-induced inhibition of the Rhosignaling pathway activates PPARa and induces HDL apo A-I. J Clin Invest 2001;107:1423–32.

103 .- Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med2004;350:1505–15.

104 .- de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002;105:2159–65.

105 .- Guyton JR. Combination drug therapy for combined hyperlipidemia. Curr Cardiol Rep 1999;1:244–50.

106 .- Streja D. Combination therapy for the treatment of dyslipidemia. Curr Opin Invest Drugs 2004;5:306–12.

107 .- Vega GL, Ma PT, Cater NB, et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hiperlipidemia and metabolic syndrome. Am J Cardiol 2003;91:956–60.

108 .- Pauciullo P, Borgnino C, Paoletti R, et al. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis 2000;150:429–36.

109 .- Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother2001;35:908–17.

110 .- Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr Med Res Opin 2003;19:155–68.